Albany handed safety-net hospitals a gift decades ago. Now some of those hospitals are using it to buy up competitors, pad balance sheets, and let poor patients fend for themselves.
That’s the argument at the center of a growing fight over New York’s handling of the federal 340B Drug Discount Program, a decades-old federal initiative designed to let safety-net hospitals purchase prescription drugs at steep discounts and pass those savings to low-income patients. The State Senate’s current budget proposal, critics say, would make a broken system worse.
The numbers are hard to explain away. Just 29% of 340B funds in New York are flowing to ZIP codes below the state median income level. Read that again. A program built to help poor patients is spending nearly three-quarters of its money in areas that don’t qualify as low-income by the state’s own measure.
It gets worse.
Between 2014 and 2022, hospitals participating in 340B watched their assets climb by 38%. Charity care, the metric hospitals use to justify their participation in the program, fell by 29% over the same stretch. Today, 85% of these hospitals provide charity care at rates below the national average. So the hospitals got richer. The poor patients got less.
The consolidation story is just as ugly. From 2016 to 2022, 75% of organizations acquired by major hospital systems were 340B facilities. Large hospital networks have been snapping up these sites not to serve more low-income patients but to capture the program’s financial incentives, locking in market share while squeezing out the independent pharmacies and community clinics that actually know their neighborhoods. Government health plans in New York have been losing roughly $89 million a year as a result.
Cancer patients are getting hit from a different angle. A study by the American Cancer Society found that “the financial incentives associated with 340B directly impact what a cancer patient pays for their care, the higher the cost of the drug used, the greater the amount cancer patients pay in cost sharing.” So a program meant to reduce costs for vulnerable patients is, in practice, pushing some of the sickest people toward more expensive treatments because that’s where the hospital’s incentive lies.
None of this is a secret. What is a problem is that Albany, so far, hasn’t fixed it.
The State Senate’s budget proposal doesn’t close the loopholes that let large hospital systems exploit 340B. It doesn’t add new transparency requirements. It doesn’t create any mechanism to track whether the discounts are actually reaching patients at the pharmacy counter or just disappearing into a hospital system’s operating budget. A hospital can save millions through 340B right now and face no obligation to tell anyone how those savings were spent. Not regulators. Not patients. Nobody.
The timing couldn’t be worse. Federal Medicaid dollars are tightening. The cost of living in this city keeps rising. Pharmacy closures are already hitting low-income neighborhoods hard, pushing patients who can least afford it into higher-cost hospital settings for care they used to get around the corner. If 340B facilities keep concentrating in large urban centers while community pharmacies close, the people the program was built to serve end up with fewer options and higher bills. Not better access. Less.
This is worth following closely, as amNewYork has been tracking the debate over the Senate’s budget language and the calls for reform coming from patient advocates and healthcare policy groups.
The path forward isn’t complicated, even if the politics are. The Senate should tighten reporting requirements so there’s a real paper trail on how 340B savings are spent. It should close the acquisition loopholes that let hospital systems use the program as a consolidation tool. And it should build in safeguards that actually connect the discounts to patient out-of-pocket costs, the whole point of the program in the first place.
Big hospital systems have lawyers, lobbyists, and decades of experience working Albany. Low-income patients in pharmacy deserts don’t.
The legislature knows what’s happening here. The data exists. The American Cancer Society study exists. The $89 million annual loss to government health plans exists. At some point, choosing not to fix a problem is its own kind of policy decision, and the people paying for that decision aren’t the ones with corner offices in Midtown.
The budget deadline is approaching. The Senate still has time to revise the language. Whether it will is another question entirely.